Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) shares dropped 1.2% on Tuesday . The company traded as low as $22.31 and last traded at $22.34. Approximately 111,114 shares changed hands during trading, an increase of 122% from the average daily volume of 50,104 shares. The stock had previously closed at $22.60.
Neoleukin Therapeutics Stock Performance
The stock's fifty day moving average is $19.55 and its two-hundred day moving average is $16.89. The firm has a market capitalization of $214.37 million, a price-to-earnings ratio of -7.33 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
